Compare DPRO & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DPRO | MDWD |
|---|---|---|
| Founded | 1998 | 2000 |
| Country | Canada | Israel |
| Employees | N/A | N/A |
| Industry | Aerospace | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 188.8M | 181.1M |
| IPO Year | 2019 | 2013 |
| Metric | DPRO | MDWD |
|---|---|---|
| Price | $6.48 | $13.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $15.00 | ★ $36.00 |
| AVG Volume (30 Days) | ★ 1.2M | 83.9K |
| Earning Date | 05-11-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $158.69 | $48.92 |
| Revenue Next Year | $131.85 | $35.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.78 | $12.52 |
| 52 Week High | $14.37 | $20.30 |
| Indicator | DPRO | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | 76.83 | 45.26 |
| Support Level | $6.07 | N/A |
| Resistance Level | $6.56 | $15.08 |
| Average True Range (ATR) | 0.30 | 0.44 |
| MACD | 0.20 | 0.01 |
| Stochastic Oscillator | 92.95 | 46.43 |
Draganfly Inc is a Canada based company. It is engaged in the provision of engineering services and the manufacture of commercial unmanned vehicle systems and software. The company operates in Canada, the United States, and Internationally. The two segments are Drones, and Corporate. The Drones segment derives its revenue from products and services related to the sale of unmanned aerial vehicles (UAV). The Corporate segment includes all costs not directly associated with the Drone and Vital segments. It generates majority of its revenue from Drones segment.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.